bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the closing of its initial public offering of 6,832,352 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 891,176 additional shares of common stock. All of the shares in the offering were offered by bluebird bio. The company’s common stock is listed on The NASDAQ Global Select Market under the trading symbol “BLUE.”
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the closing of its initial public offering of 6,832,352 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 891,176 additional shares of common stock. All of the shares in the offering were offered by bluebird bio. The company’s common stock is listed on The NASDAQ Global Select Market under the trading symbol “BLUE.”
Help employers find you! Check out all the jobs and post your resume.